Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Chemokine Receptor CXCR4-targeting PET Imaging for Thymoma

ID
Name
PUMCH-CXCR4-thymoma
Description
Chemokine receptor CXCR4 was expressed in T cells and CXCR4-targeting molecular imaging- 68Ga-Pentixafor PET/CT could be a promising technique to evaluate the extent of thymoma with higher accuracy. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, distinguish evaluation for thymoma.
Trial arms
Trial start
2023-06-22
Estimated PCD
2024-12-31
Trial end
2024-12-31
Status
Recruiting
Phase
Early phase I
Treatment
68Ga-Pentixafor
Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions of thymoma by PET/CT.
Arms:
68Ga-Pentixafor, PET/CT
Other names:
68Ga-CXCR4
Size
100
Primary endpoint
SUVmax and SUVmean
through study completion, an average of 1.5 years
Eligibility criteria
Inclusion Criteria: * suspected or confirmed untreated thymoma patients * signed written consent. Exclusion Criteria: * pregnancy * breastfeeding * known allergy against Pentixafor * any medical condition that in the opinion of the investigator,may * significantly interfere with study compliance.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['EARLY_PHASE1'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}
Updated at
2023-10-17

1 organization

1 product

1 indication

Organization
Peking Union Medical College Hospital
Product
68Ga-Pentixafor
Indication
Thymoma